Zobrazeno 1 - 10
of 2 462
pro vyhledávání: ''
Autor:
Joshua S. Friedman, Tomi Jun, Omid Rashidipour, Kuan-lin Huang, Ethan Ellis, Priyanka Kadaba, Puneet Belani, Kambiz Nael, Nadejda M. Tsankova, Robert Sebra, Adília Hormigo
Publikováno v:
Cancer Immunology, Immunotherapy. 72:1893-1901
Autor:
Alessandro Rizzo, Veronica Mollica, Valentina Tateo, Elisa Tassinari, Andrea Marchetti, Matteo Rosellini, Raffaele De Luca, Matteo Santoni, Francesco Massari
Publikováno v:
Cancer Immunology, Immunotherapy. 72:1381-1394
Autor:
E. Pons-Tostivint, P. Hulo, V. Guardiolle, L. Bodot, A. Rabeau, M. Porte, S. Hiret, P. Demontrond, H. Curcio, A. Boudoussier, R. Veillon, M. Mayenga, C. Dumenil, T. Chatellier, P. A. Gourraud, J. Mazieres, J. Bennouna
Publikováno v:
Cancer Immunology, Immunotherapy. 72:1881-1890
Introduction Pembrolizumab alone (IO-mono) or in combination with platinum-based chemotherapy (CT-IO) is first-line standard of care for advanced non-small cell lung cancer (NSCLC) patients with PD-L1 ≥ 50%. This retrospective multicentre study ass
Publikováno v:
Cancer Immunology, Immunotherapy. 72:1835-1851
Radioresistance and immunosuppression remain the major obstacles in the anti-cancer treatments. This work studies the functions of sialic acid binding Ig like lectin 9 (SIGLEC9) and its related molecules in radioresistance and immunosuppression in es
Autor:
Sho Wakasu, Tetsuzo Tagawa, Naoki Haratake, Fumihiko Kinoshita, Yuka Oku, Yuki Ono, Tomoyoshi Takenaka, Yoshinao Oda, Mototsugu Shimokawa, Masaki Mori
Publikováno v:
Cancer Immunology, Immunotherapy. 72:1823-1834
Background: Ectopic lymphoid formations are called tertiary lymphoid structures (TLSs). TLSs in cancer have been reported to be associated with good prognosis and immunotherapy response. However, the relationship between TLSs and lymph node (LN) meta
Autor:
Chih-Liang Wang, Ai-Sheng Ho, Chun-Chao Chang, Zong-Lin Sie, Cheng-Liang Peng, Jungshan Chang, Chun-Chia Cheng
Publikováno v:
Cancer Immunology, Immunotherapy. 72:1865-1880
Radiotherapy (RT) not only damages tumors but also induces interferon (IFN) expression in tumors. IFNs mediate PD-L1 to exhaust CD8+ T cells, but which also directly impact tumor cells and potentially activate anti-tumor immune surveillance. Little i
Autor:
Anna Siemiątkowska, Maciej Bryl, Katarzyna Kosicka-Noworzyń, Jakub Tvrdoň, Iwona Gołda-Gocka, Franciszek K. Główka
Publikováno v:
Cancer Immunology, Immunotherapy. 72:1853-1863
Background Immunotherapy has changed the paradigm of treating non-small cell lung cancer (NSCLC). But, selecting patients who will achieve long-term benefits from treatment remains unsatisfactory. Here, we investigated the possible use of the soluble
Autor:
Shengdong Wang, Hengyuan Li, Tao Chen, Hao Zhou, Wenkan Zhang, Nong Lin, Xiaohua Yu, Yu Lou, Binghao Li, Eloy Yinwang, Zenan Wang, Keyi Wang, Yucheng Xue, Hao Qu, Peng Lin, Hangxiang Sun, Wangsiyuan Teng, Haochen Mou, Xupeng Chai, Zhijian Cai, Zhaoming Ye
Publikováno v:
Cancer Immunology, Immunotherapy. 72:1803-1821
Human Vγ9Vδ2 T cells have attracted considerable attention as novel alternative antigen-presenting cells (APCs) with the potential to replace dendritic cells in antitumor immunotherapy owing to their high proliferative capacity and low cost. Howeve
Autor:
Femke A. I. Ehlers, Niken M. Mahaweni, Annet van de Waterweg Berends, Thara Saya, Gerard M. J. Bos, Lotte Wieten
Publikováno v:
Cancer Immunology Immunotherapy, 72(6), 1789-1801. Springer
Multiple myeloma (MM) is an incurable disease, characterized by malignant plasma cells in the bone marrow. MM growth is largely dependent on the tumor microenvironment (TME), consisting of complex cellular networks that shape a tumor-permissive envir
Autor:
Cho-Han Chiang, Yuan-Jen Chen, Cho-Hsien Chiang, Cheng-Ying Chen, Yu-Cheng Chang, Shih-Syuan Wang, Xin Ya See, Chuan-Sheng Horng, Chun-Yu Peng, Yuan Ping Hsia, Cheng-Ming Peng, Cho-Hung Chiang
Publikováno v:
Cancer Immunology, Immunotherapy. 72:1951-1956